Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine

10 Aug 2022

Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.

Deal Watch 2021 — • Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Less than two years after going public in a special purpose acquisition corporation merger spearheaded by Foresite Capital, Gemini...